The firm provides end-to-end support for radiopharmaceuticals, biologics, and cell and gene therapy programs. By managing everything from initial capital project planning to regulatory readiness and operational startup, the company has capitalized on the surging demand for specialized manufacturing expertise. Their personnel currently represent over 600 years of collective experience in nuclear medicine.

CEO Emilie Pelletier credits the rapid expansion to a focus on hands-on execution and technical precision in navigating the shift from therapy concept to commercialization. As the industry faces mounting pressure to deliver life-saving treatments, the consultancy has positioned itself as a critical partner for organizations struggling with the complexities of advanced facility design and process optimization.